Avenue Therapeutics Dividend

Dividend criteria checks 0/6

Avenue Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.3%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$17.58
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ATXI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATXI's dividend payments have been increasing.

Dividend Yield vs Market

Avenue Therapeutics Dividend Yield vs Market

How does ATXI dividend yield compare to the market?
Segment	Dividend Yield
Company (ATXI)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Pharmaceuticals)	2.3%
Analyst forecast in 3 Years (ATXI)	n/a

Notable Dividend: Unable to evaluate ATXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ATXI's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ATXI has not reported any payouts.

Avenue Therapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Now 570% overvalued after recent price rise

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

New major risk - Share price stability

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics shares slide on pricing $12M securities offering

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: US$6.93

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics issues regulatory update for IV tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

New 90-day low: US$2.95

Avenue Therapeutics, Inc. Receives Complete Response Letter from the FDA for IV Tramadol

New 90-day low: US$4.53

Price target lowered to US$9.00

New 90-day high - US$12.06

New 90-day high - US$11.68

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies